🔎 Trials Near Me

Beranda › Kanker Endometrium › Florida

Uji klinis Kanker Endometrium di Florida

65 studi untuk Kanker Endometrium mencari peserta di lokasi di Florida.

Kota di Florida

Teks studi resmi (Bahasa Inggris)

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

  • UM Sylvester Comprehensive Cancer Center at Aventura, Aventura
  • UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables
  • UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach
  • dan 6 lainnya
Menerima pesertaFase 2
Semua usia · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05564377

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • University of Miami - Sylvester Comprehensive Cancer Center, Miami
  • Advent Health, Orlando
  • Florida Cancer Specialists South, Port Charlotte
Menerima pesertaFase 1/2
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT04585750

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

  • Sarasota Memorial Hospital-Venice, N. Venice
  • Florida Cancer Specialists - Sarasota Downtown, Sarasota
  • FPG - Surgical Oncology Clinics Gynecologic Oncology Surgery, Sarasota
  • dan 3 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Wanita · Diperbarui 2 Okt 2026 · NCT07198074

A Phase 1 Study of the Safety and Tolerability of CTX-10726

  • Mayo Clinic Florida, Jacksonville
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT07419841

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

  • Florida Cancer Specialists & Research Institute - Fort Myers Cancer Center - Gladiolus, Fort Myers
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06760819

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

  • AdventHealth Cancer Institute, Orlando
Menerima pesertaFase 1
Usia 19 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06586957

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

  • AdventHealth Medical Group Oncology Research at Celebration, Kissimmee
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06172478

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

  • Mayo Clinic, Jacksonville
  • Genoma Research, Inc., Miami
  • Orlando Health, Orlando
  • dan 1 lainnya
Menerima pesertaStudi observasional
Usia 18 ke atas · Wanita · Diperbarui 29 Sep 2026 · NCT05051722

Study of AVZO-021 in Patients With Advanced Solid Tumors

  • Avenzo Therapeutics Recruiting Site, Sarasota
  • Avenzo Therapeutics Recruiting Site, Tampa
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT05867251

DESTINY-PANTUMOUR04

  • Research Site, Coral Springs
  • Research Site, St. Petersburg
  • Research Site, West Palm Beach
Menerima pesertaStudi observasional
Usia 18 hingga 130 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07124000

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

  • Research Site, Jacksonville
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06218914

Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Progression on or Following First-Line Immunotherapy Maintenance

  • University of Miami, Miami
Menerima pesertaFase 2
Usia 18 ke atas · Wanita · Diperbarui 24 Sep 2026 · NCT07594015

Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

  • UM Sylvester Comprehensive Cancer Center at, Deerfield Beach
  • UM Sylvester Comprehensive Cancer Center at Doral, Doral
  • University of Florida, Gainesville
  • dan 9 lainnya
Menerima pesertaFase 2
Usia 18 ke atas · Wanita · Diperbarui 24 Sep 2026 · NCT05640999

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

  • Florida Cancer Specialists, Sarasota
  • Moffitt Cancer Center and Research Institute, Tampa
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT06128551

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

  • Moffitt, Tampa
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07114601

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

  • Omnicure Clinical Research, Doral
  • Bioresearch Partner, Hialeah
  • Florida Clinical Trials Group, Plantation
  • dan 1 lainnya
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07262619

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

  • Sylvester Comprehensive Cancer Center, Miami
  • Sara Cannon Research Institute Lake Nona, Orlando
  • Hematology - Oncology Associates of the Treasure Coast, Port Saint Lucie
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Sep 2026 · NCT05983432

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

  • Florida Cancer Specialists - South ( Site 7003), Fort Myers
  • UF Health Davis Cancer Pavilion and Shands Med Plaza ( Site 6026), Gainesville
  • Mount Sinai Braman Comprehensive Cancer Center ( Site 6031), Miami Beach
  • dan 3 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Wanita · Diperbarui 17 Sep 2026 · NCT06952504

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

  • Florida Cancer Specialists - Lake Nona, Orlando
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT07109726

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

  • Broward Health Medical Center, Fort Lauderdale
Menerima pesertaFase 3
Usia 18 ke atas · Wanita · Diperbarui 17 Sep 2026 · NCT06340568

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

  • Memorial Healthcare System, Hollywood
  • The Oncology Institute of Hope & Innovation, Lakeland
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT05059444

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

  • University of Miami, Miami
  • Sarah Cannon Research Institute - Lake Nona Florida, Orlando
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Sep 2026 · NCT06293898

Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

  • SMH - Sarasota - Main Campus, Sarasota
  • Women's Care - 9th Ave, St. Petersburg
  • Women's Care - Armenia Ave, Tampa
Menerima pesertaFase 3
Usia 18 ke atas · Wanita · Diperbarui 9 Sep 2026 · NCT07166094

Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.

  • Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando
Menerima pesertaFase 1
Usia 18 ke atas · Wanita · Diperbarui 3 Sep 2026 · NCT07755436

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

  • Research Site, Fort Myers
  • Research Site, Miami
  • Research Site, Miami Beach
  • dan 4 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Wanita · Diperbarui 3 Sep 2026 · NCT06989112

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

  • Florida Cancer Specialists, Orlando
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 27 Agu 2026 · NCT07186842

Endometrial Cancer Vaginal Fluid Specimen Collection Study

  • Physical Care Clinical Research, Sarasota
Menerima pesertaStudi observasional
Usia 18 ke atas · Wanita · Diperbarui 27 Agu 2026 · NCT07544680

A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

  • SCRI FCS Sarasota, Sarasota
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 27 Agu 2026 · NCT07227168

A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

  • H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc., Tampa
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 26 Agu 2026 · NCT07383506

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

  • Moffitt Cancer Center, Tampa
Menerima pesertaFase 1
Usia 15 ke atas · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT06276491

A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

  • Mount Sinai Comprehensive Cancer Center, Miami Beach
Menerima pesertaFase 2
Usia 18 ke atas · Wanita · Diperbarui 21 Agu 2026 · NCT05548296

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

  • Mayo Clinic in Florida, Jacksonville
Menerima pesertaFase 1/2
Usia 16 ke atas · Semua jenis kelamin · Diperbarui 20 Agu 2026 · NCT05269381

A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

  • SCRI - Florida Cancer Specialists, Sarasota
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Agu 2026 · NCT07470853

FOG-001 in Locally Advanced or Metastatic Solid Tumors

  • Mayo Clinic, Jacksonville
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT05919264

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

  • AdventHealth Celebration, Celebration
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Agu 2026 · NCT05592626

Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease

  • Miami Cancer Institute Baptist Health South Florida, Miami
  • ADVENTHEALTH (Data collection only), Orlando
Menerima pesertaStudi observasional
Usia 18 ke atas · Wanita · Diperbarui 7 Agu 2026 · NCT04291612

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

  • USOR Florida Cancer Specialists South, Fort Myers
  • USOR Florida Cancer Specialists North, St. Petersburg
  • USOR Florida Cancer Specialists East, West Palm Beach
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Agu 2026 · NCT05579366

Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma

  • University of Miami, Miami
Menerima pesertaFase 1
Usia 18 ke atas · Wanita · Diperbarui 3 Agu 2026 · NCT05603910

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

  • Florida Cancer Specialists, Fort Myers
  • Mayo Clinic (Florida), Jacksonville
  • Cancer Specialists of North Florida, Jacksonville
  • dan 2 lainnya
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Jul 2026 · NCT04657068

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.